This brand name is authorized in Estonia, Croatia, Ireland, Lithuania, New Zealand, Poland, Tunisia, South Africa

Active ingredients

The drug ABEVMY contains one active pharmaceutical ingredient (API):

1 Bevacizumab

Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.

Read about Bevacizumab

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01FG01 Bevacizumab L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
Discover more medicines within L01FG01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1846841, 1846852, 1846863, 1846874, 1846885
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1092483, 1092484, 1092485, 1092486, 1092487
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 21621
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100449085
Country: TN Direction de la Pharmacie et du Médicament Identifier(s): 20343021H, 20343022H
Country: ZA Health Products Regulatory Authority Identifier(s): 55/26/0256, 55/26/0257

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.